The Institute for Clinical and Economic Review (ICER) is an organization in the U.S. that evaluates drugs and their cost-effectiveness.
Though they claim to be un-biased and patient focused, ICER consistently ignores Patient Reported Outcome (PRO) data when compiling their reports, the results of which are framed in a way that benefits their funding partners in the insurance industry.
Though GHLF challenges the validity of the reports altogether, ICER’s reports matter. More than half of insurance companies – including Express Scripts and Blue Shield of California – have been known to cite and consult ICER reports when publicly discussing coverage decisions.
It’s alarming that there isn’t any statutory oversight, fact-checking and worst of all, transparency within that process.
GHLF calls conclusions from ICER’s draft on osteoporosis treatments anti-patient and methodologically flawed.⇀ READ MORE
A report on rheumatoid arthritis treatment released by ICER risks restricting patients’ drug access, critics say.⇀ READ MORE
CreakyJoints offered its strong objection to the Institute for Clinical and Economic Review’s (ICER) Rheumatoid Arthritis: Evidence Report.⇀ READ MORE